Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Research

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins

Authors: Xiaoyong Zheng, Jian Zhuge, Stephania M Bezerra, Sheila F Faraj, Enrico Munari, John T Fallon, Ximing J Yang, Pedram Argani, George J Netto, Minghao Zhong

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access

Abstract

TERT promoter mutations were recently discovered in melanoma by next generation sequencing. Subsequently, several malignancies including urothelial carcinoma were also found to be associated with the same TERT promoter mutations. Small cell carcinoma (SCC) of the urinary bladder is a rare subtype with an aggressive clinical course. Despite the frequent occurrence of TERT promoter mutations in urothelial carcinoma, the incidence of the mutations in SCC of the urinary bladder is unknown. In addition, as a potential molecular marker to distinguish SCC of the urinary bladder from SCC of the prostate, lung (SCLC) and other origins, this information may be clinically useful. We collected a total of 11 cases of SCC of the urinary bladder (10 cases are primary SCC of the urinary bladder; 1 case has primary SCC of the urinary bladder and liver metastasis). We also included 20 cases of SCLC, 2 cases of SCC of the prostate, 5 cases of Merkel cell carcinoma, and 6 cases of SCC from other sites (cervical, GE junction, breast, and soft tissue). In addition, 3 cases of non-neoplastic tissue from the matched SCC of bladder patient and 14 cases of benign urinary bladder were also included. All tumor sections have been examined to confirm the diagnosis and to make sure more than 20% are of tumor content. Genomic DNA was isolated from FFPE tissue and a fragment of the TERT promoter (145 bp) was amplified by PCR. The TERT promoter mutations are determined by bi-directional Sanger sequencing. All (11/11) SCC of the urinary bladder bear TERT promoter mutation C228T. Neither of SCC from all other origins nor matched non-neoplastic tissue contains the TERT promoter mutations. We demonstrated a high frequency TERT promoter mutation in SCC of the urinary bladder, but not in SCC of other origin, such as the prostate. The findings further illustrate molecular differences between SCC of the urinary bladder and SCC of other origins, despite their shared morphologic and immunophenotypic similarities. The TERT promoter mutation may be a biomarker differentiating SCC of the urinary bladder from SCC of other origins.
Appendix
Available only for authorised users
Literature
1.
go back to reference Palmgren JS, Karavadia SS, Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007, 34: 22-29. 10.1053/j.seminoncol.2006.10.026.CrossRefPubMed Palmgren JS, Karavadia SS, Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007, 34: 22-29. 10.1053/j.seminoncol.2006.10.026.CrossRefPubMed
2.
go back to reference Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ: ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011, 24: 820-828. 10.1038/modpathol.2011.7.PubMedCentralCrossRefPubMed Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ: ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011, 24: 820-828. 10.1038/modpathol.2011.7.PubMedCentralCrossRefPubMed
3.
go back to reference Smekalova EM, Shubernetskaya OS, Zvereva MI, Gromenko EV, Rubtsova MP, Dontsova OA: Telomerase RNA biosynthesis and processing. Biochemistry (Mosc). 2012, 77: 1120-1128. 10.1134/S0006297912100045.CrossRef Smekalova EM, Shubernetskaya OS, Zvereva MI, Gromenko EV, Rubtsova MP, Dontsova OA: Telomerase RNA biosynthesis and processing. Biochemistry (Mosc). 2012, 77: 1120-1128. 10.1134/S0006297912100045.CrossRef
4.
go back to reference Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science. 2013, 339: 959-961. 10.1126/science.1230062.CrossRefPubMed Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science. 2013, 339: 959-961. 10.1126/science.1230062.CrossRefPubMed
5.
go back to reference Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 2013, 339: 957-959. 10.1126/science.1229259.PubMedCentralCrossRefPubMed Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 2013, 339: 957-959. 10.1126/science.1229259.PubMedCentralCrossRefPubMed
6.
go back to reference Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110: 6021-6026. 10.1073/pnas.1303607110.PubMedCentralCrossRefPubMed Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110: 6021-6026. 10.1073/pnas.1303607110.PubMedCentralCrossRefPubMed
7.
go back to reference Cheuk W, Kwan MY, Suster S, Chan JK:Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001, 125: 228-231.PubMed Cheuk W, Kwan MY, Suster S, Chan JK:Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001, 125: 228-231.PubMed
8.
go back to reference Alijo Serrano F, Sanchez-Mora N, Angel Arranz J, Hernandez C, Alvarez-Fernandez E:Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol. 2007, 128: 733-739. 10.1309/HTREM6QYQDYGNWYA.CrossRefPubMed Alijo Serrano F, Sanchez-Mora N, Angel Arranz J, Hernandez C, Alvarez-Fernandez E:Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol. 2007, 128: 733-739. 10.1309/HTREM6QYQDYGNWYA.CrossRefPubMed
9.
go back to reference Jonathan I: Epstein GJN: Biopsy Interpretation of the Prostate. Fourth Edition edn. 2008, Lippincott, Williams & Wilkins, Philadelphia Jonathan I: Epstein GJN: Biopsy Interpretation of the Prostate. Fourth Edition edn. 2008, Lippincott, Williams & Wilkins, Philadelphia
10.
go back to reference Wang W, Epstein JI:Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008, 32: 65-71. 10.1097/PAS.0b013e318058a96b.CrossRefPubMed Wang W, Epstein JI:Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008, 32: 65-71. 10.1097/PAS.0b013e318058a96b.CrossRefPubMed
11.
go back to reference Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L, Hatem F, Huang J: Anthony di Sant'Agnese P: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006, 30: 705-712. 10.1097/00000478-200606000-00005.CrossRefPubMed Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L, Hatem F, Huang J: Anthony di Sant'Agnese P: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006, 30: 705-712. 10.1097/00000478-200606000-00005.CrossRefPubMed
12.
go back to reference Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan CX, Baldridge LA:Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005, 166: 1533-1539. 10.1016/S0002-9440(10)62369-3.PubMedCentralCrossRefPubMed Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan CX, Baldridge LA:Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005, 166: 1533-1539. 10.1016/S0002-9440(10)62369-3.PubMedCentralCrossRefPubMed
13.
go back to reference Gaisa NT, Tilki D, Losen I, Dahl E, Stoehr R, Stief CG, Knuchel R: Insights from a whole cystectomy specimen–association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. Hum Pathol. 2008, 39: 1258-1262. 10.1016/j.humpath.2007.12.017.CrossRefPubMed Gaisa NT, Tilki D, Losen I, Dahl E, Stoehr R, Stief CG, Knuchel R: Insights from a whole cystectomy specimen–association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. Hum Pathol. 2008, 39: 1258-1262. 10.1016/j.humpath.2007.12.017.CrossRefPubMed
14.
go back to reference Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM:Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014, 46: 427-429. 10.1038/ng.2928.PubMedCentralCrossRefPubMed Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM:Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014, 46: 427-429. 10.1038/ng.2928.PubMedCentralCrossRefPubMed
15.
go back to reference Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, Gao J, Schultz N, Gonen M, Soslow RA, Berger MF, Levine DA:Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014, 46: 424-426. 10.1038/ng.2922.CrossRefPubMed Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, Gao J, Schultz N, Gonen M, Soslow RA, Berger MF, Levine DA:Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014, 46: 424-426. 10.1038/ng.2922.CrossRefPubMed
16.
go back to reference Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M:Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013, 12: 1637-1638. 10.4161/cc.24662.PubMedCentralCrossRefPubMed Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M:Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013, 12: 1637-1638. 10.4161/cc.24662.PubMedCentralCrossRefPubMed
17.
go back to reference Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA: Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX: Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014, 65: 360-366. 10.1016/j.eururo.2013.08.052.CrossRefPubMed Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA: Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX: Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014, 65: 360-366. 10.1016/j.eururo.2013.08.052.CrossRefPubMed
18.
go back to reference Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ:TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013, 73: 7162-7167. 10.1158/0008-5472.CAN-13-2498.PubMedCentralCrossRefPubMed Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ:TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013, 73: 7162-7167. 10.1158/0008-5472.CAN-13-2498.PubMedCentralCrossRefPubMed
Metadata
Title
High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins
Authors
Xiaoyong Zheng
Jian Zhuge
Stephania M Bezerra
Sheila F Faraj
Enrico Munari
John T Fallon
Ximing J Yang
Pedram Argani
George J Netto
Minghao Zhong
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-014-0047-7

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine